Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Immuneering's oncology programs target mutations of the MAPK and mTOR pathways, which run parallel to each other and are inappropriately activated in over half of all cancers. The company's lead program, IMM-1-104, is a highly selective dual-MEK inhibitor being developed for the treatment of advanced solid tumor patients harboring RAS mutant tumors. Immuneering plans to submit an IND for IMM-1-104 in the first quarter of 2022 and anticipates filings at least one additional oncological IND in both 2023 and 2024.
The Cambridge, MA-based company was founded in 2008 and plans to list on the Nasdaq under the symbol IMRX. Immuneering filed confidentially on May 13, 2021. Morgan Stanley, Jefferies, Cowen, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
